(Reuters) - KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG, Bloomberg News reported on Thursday, citing people familiar with the matter.

Warburg Pincus, which was also a part of the consortium, is still working to see if it can reach a deal, the report said.

Earlier this month, Reuters reported that a consortium including KKR and Warburg Pincus had submitted a non-binding bid for Gerresheimer.

Gerresheimer, which makes pens used to inject weight-loss drugs such as Novo Nordisk's Wegovy, has a market capitalization of about 2.22 billion euros, according to LSEG data.

The consortium had submitted a bid at about 90 euros a share, which would value the company at nearly 3.1 billion euros ($3.42 billion).

Gerresheimer and Warburg Pincus declined to comment while KKR did not immediately respond to Reuters' requests for comment.

In February, the German company said it was in early-stage discussions with private equity investors over a potential sale of the company.

Gerresheimer said at that time that the interest was informal and on a non-binding basis.

($1 = 0.9065 euros)